Analysis Affinity of Anti-CD20 Antibody (Rituximab) by KinExA (CAT#: STEM-MB-0020-CJ)

Name: Analysis Affinity of Anti-CD20 Antibody (Rituximab) by KinExA
SKU: STEM-MB-0020-CJ
Rating: 5 (1 reviews)

Introduction

Rituximab, a monoclonal antibody against CD20, is a component of standard therapy for systemic DLBCL (R-CHOP). Since most patients with PCNSL have CD20, rituximab may also play a role in the treatment of PCNSL. At the same time, intraventricular administration of rituximab has also been shown to be feasible and possibly active.

Buy Now

Principle Applications Procedure Materials

Principle

KinExA is a two-stage analysis system. In the first stage, a number of solutions are prepared, where one partner remains constant (constant binding partner, or CBP) and the other (titrant) is variable, usually serially diluted. As the titrant is added, the free CBP decreases and is analysed by a sophisticated and precise microfluorescence measurement device. The signal generated can be mathematically related to the affinity (KD) of the two molecules for each other, as well as the kinetic parameters of binding (kon) and dissociation (koff).

Applications

Virology;Pharmacology

Procedure

1. preparation of the functionalized beads which will capture the analyte for measuremen.
2. preparation of a series of solutions consisting of a constant initial concentration of one component of the binary reaction and serial dilutions of the other reactant. The component that is kept constant is the constant binding partner (CBP) , and is the one which will be analyzed.
3. each reaction mixture is sampled and the fluorescence of free CBP bound to the capture beads is obtained for subsequent numerical analysis.